Paul M. is a senior scientist specializing in cellular immunology, currently working at Merck since 2024. With over a decade of experience, they previously held roles at organizations like Parker Institute for Cancer Immunotherapy, where their research focused on cancer vaccine development, and Nurix Therapeutics, where they analyzed clinical trial data. Paul earned a PhD in Microbiology from the University of Washington - School of Medicine and a BS in Microbiology and Chemistry, graduating magna cum laude from Oregon State University. They possess expertise in various advanced techniques, including flow cytometry and bioinformatics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices